Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
endocrine system diseases | D004700 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
INVOKAMET | Johnson & Johnson | N-204353 RX | 2014-08-08 | 4 products, RLD, RS |
INVOKAMET XR | Johnson & Johnson | N-205879 RX | 2016-09-20 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
XIGDUO XR | AstraZeneca | N-205649 RX | 2014-10-29 | 5 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
QTERNMET XR | AstraZeneca | N-210874 DISCN | 2019-05-02 | 4 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TRIJARDY XR | Boehringer Ingelheim | N-212614 RX | 2020-01-27 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SYNJARDY | Boehringer Ingelheim | N-206111 RX | 2015-08-26 | 4 products, RLD, RS |
SYNJARDY XR | Boehringer Ingelheim | N-208658 RX | 2016-12-09 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SEGLUROMET | Merck & Co | N-209806 RX | 2017-12-19 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
METAGLIP | Bristol Myers Squibb | N-021460 DISCN | 2002-10-21 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
GLUCOVANCE | Bristol Myers Squibb | N-021178 DISCN | 2000-07-31 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JENTADUETO | Boehringer Ingelheim | N-201281 RX | 2012-01-30 | 3 products, RLD, RS |
JENTADUETO XR | Boehringer Ingelheim | N-208026 RX | 2016-05-27 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FORTAMET | Andrx Corporation | N-021574 RX | 2004-04-27 | 1 products, RLD |
GLUMETZA | Santarus | N-021748 RX | 2005-06-03 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PRANDIMET | Novo Nordisk | N-022386 DISCN | 2008-06-23 | 2 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AVANDAMET | SB Pharmco | N-021410 DISCN | 2002-10-10 | 5 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
KOMBIGLYZE XR | AstraZeneca | N-200678 DISCN | 2010-11-05 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZITUVIMET | Zydus Therapeutics | N-216743 RX | 2023-11-03 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JANUMET | Merck & Co | N-022044 RX | 2007-03-30 | 2 products, RLD, RS |
JANUMET XR | Merck & Co | N-202270 RX | 2012-02-02 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
actoplus met | New Drug Application | 2024-06-28 |
alogliptin and metformin hydrochloride | NDA authorized generic | 2024-02-12 |
appformin | unapproved drug other | 2011-08-08 |
appformin-d | unapproved drug other | 2011-08-08 |
avandamet | New Drug Application | 2012-08-30 |
dapagliflozin and metformin hydrochloride | NDA authorized generic | 2024-06-12 |
fortamet | New Drug Application | 2010-03-15 |
glipizide and metformin hydrochloride | ANDA | 2018-12-11 |
glipizide and metformin hydrochloride glipizide and metformin hydrochloride | ANDA | 2023-10-30 |
glipizide and metformin hcl | ANDA | 2024-02-21 |
Expiration | Code | ||
---|---|---|---|
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY, BOEHRINGER INGELHEIM | |||
2026-12-20 | PED | ||
2026-06-20 | NPP | ||
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY XR, BOEHRINGER INGELHEIM | |||
2026-12-20 | PED | ||
2026-06-20 | M-296 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO, BOEHRINGER INGELHEIM | |||
2026-12-20 | PED | ||
2026-06-20 | M-295 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO XR, BOEHRINGER INGELHEIM | |||
2026-12-20 | PED | ||
2026-06-20 | M-295 | ||
ALOGLIPTIN BENZOATE / METFORMIN HYDROCHLORIDE, KAZANO, TAKEDA PHARMS USA | |||
2026-07-27 | M-300 | ||
ERTUGLIFLOZIN / METFORMIN HYDROCHLORIDE, SEGLUROMET, MSD SUB MERCK | |||
2024-09-17 | M-275 | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET, MSD SUB MERCK | |||
2024-06-04 | PED | ||
2023-12-04 | M-187 | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET XR, MSD SUB MERCK | |||
2024-06-04 | PED | ||
2023-12-04 | M-187 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Metformin Hydrochloride, Riomet Er, Sun Pharm | |||
9962336 | 2035-05-01 | DP | |
Empagliflozin / Linagliptin / Metformin Hydrochloride, Trijardy Xr, Boehringer Ingelheim | |||
9949998 | 2034-06-11 | U-2290, U-2731 | |
10258637 | 2034-04-03 | U-2290, U-2731 | |
11090323 | 2034-04-03 | U-3192, U-3193 | |
11833166 | 2034-04-03 | U-3776, U-3777 | |
10596120 | 2032-03-07 | DP | U-2775, U-2776, U-2790, U-2792 |
11564886 | 2032-03-07 | DP | U-3531 |
10406172 | 2030-06-15 | DP | U-2733 |
9155705 | 2030-05-21 | DP | |
8551957 | 2029-10-14 | DP | U-2730 |
9415016 | 2029-04-02 | DP | |
10022379 | 2029-04-02 | U-2339, U-2732 | |
7579449 | 2028-08-01 | DP | |
7713938 | 2027-04-15 | DS, DP | |
8883805 | 2025-11-26 | DP | |
7407955 | 2025-05-02 | DS, DP | |
Empagliflozin / Metformin Hydrochloride, Synjardy, Boehringer Ingelheim | |||
9949997 | 2034-05-17 | U-3532, U-3533 | |
11813275 | 2034-04-03 | U-3759 | |
10610489 | 2030-09-30 | DP | |
Linagliptin / Metformin Hydrochloride, Jentadueto Xr, Boehringer Ingelheim | |||
9555001 | 2033-03-06 | DP | U-1967, U-1968 |
9173859 | 2027-05-04 | DP | U-1503 |
Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab | |||
9616028 | 2030-11-12 | DP | |
8685934 | 2030-05-26 | U-1522 | |
7919598 | 2029-12-16 | DP | |
8501698 | 2027-06-20 | DP | U-493 |
6515117 | 2025-10-04 | DS, DP | U-493 |
Ertugliflozin / Metformin Hydrochloride, Segluromet, Msd Sub Merck | |||
9308204 | 2030-10-21 | DP | |
9439902 | 2030-10-21 | U-2214 | |
8080580 | 2030-07-13 | DS, DP | U-2214 |
Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms | |||
11576894 | 2030-07-06 | DP | |
7943582 | 2029-02-26 | DS, DP | U-493, U-2441, U-2632 |
8513202 | 2027-12-03 | DS, DP | U-493, U-2441, U-2632 |
7943788 | 2027-07-14 | DS, DP | |
8222219 | 2025-04-11 | U-493, U-2441, U-2632 | |
8785403 | 2024-07-30 | DP | |
Linagliptin / Metformin Hydrochloride, Jentadueto, Boehringer Ingelheim | |||
8846695 | 2030-06-04 | U-1503 | |
10973827 | 2029-04-02 | DP | |
8673927 | 2027-05-04 | U-1503 | |
Alogliptin Benzoate / Metformin Hydrochloride, Kazano, Takeda Pharms Usa | |||
8900638 | 2029-05-24 | DP | |
7807689 | 2028-06-27 | DS, DP | U-1337 |
8288539 | 2025-06-24 | DP | |
8173663 | 2025-03-15 | U-1338 | |
Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa | |||
9320714 | 2029-02-03 | DP | |
9101660 | 2027-01-22 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 146 | 230 | 492 | 307 | 221 | 1358 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 90 | 205 | 462 | 266 | 176 | 1162 |
Healthy volunteers/patients | — | — | — | 198 | 2 | — | 2 | 11 | 213 |
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 19 | 22 | 33 | 52 | 55 | 170 |
Syndrome | D013577 | — | — | 12 | 30 | 34 | 37 | 51 | 152 |
Obesity | D009765 | EFO_0001073 | E66.9 | 9 | 30 | 19 | 32 | 38 | 121 |
Insulin resistance | D007333 | HP_0000855 | — | 7 | 27 | 21 | 27 | 21 | 95 |
Prediabetic state | D011236 | EFO_1001121 | R73.03 | 5 | 11 | 10 | 17 | 35 | 75 |
Gestational diabetes | D016640 | HP_0009800 | O24.4 | 4 | 6 | 18 | 12 | 25 | 61 |
Glucose intolerance | D018149 | HP_0000833 | R73.03 | 2 | 9 | 10 | 13 | 26 | 57 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 12 | 9 | 2 | — | 4 | 26 |
Adenocarcinoma | D000230 | — | — | 2 | 17 | 1 | — | 2 | 21 |
Carcinoma | D002277 | — | C80.0 | 5 | 15 | 3 | — | 1 | 20 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 11 | 4 | — | 3 | 19 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 13 | 1 | — | 2 | 18 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 12 | 1 | — | 2 | 15 |
Colorectal neoplasms | D015179 | — | — | 2 | 9 | 3 | — | 1 | 15 |
Recurrence | D012008 | — | — | 2 | 4 | 2 | — | 2 | 9 |
Chronic renal insufficiency | D051436 | — | N18 | — | 6 | 3 | — | 2 | 9 |
Periodontitis | D010518 | EFO_0000649 | K05.3 | — | 8 | 6 | — | 1 | 9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 11 | — | — | 4 | 20 |
Leukemia | D007938 | — | C95 | 3 | 4 | — | — | 3 | 10 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 4 | 5 | — | — | 1 | 9 |
Squamous cell carcinoma | D002294 | — | — | 4 | 5 | — | — | 1 | 9 |
Melanoma | D008545 | — | — | 3 | 7 | — | — | — | 8 |
Glioblastoma | D005909 | EFO_0000515 | — | 2 | 6 | — | — | — | 8 |
Sclerosis | D012598 | — | — | 2 | 6 | — | — | — | 7 |
Pharmacokinetics | D010599 | — | — | 5 | 1 | — | — | 1 | 7 |
Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | — | 4 | 6 |
Ovarian epithelial carcinoma | D000077216 | — | — | 3 | 3 | — | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 10 | — | — | — | 3 | 13 |
Therapeutic equivalency | D013810 | — | — | 10 | — | — | — | 2 | 12 |
Disease | D004194 | EFO_0000408 | R69 | 2 | — | — | — | 4 | 6 |
Drug interactions | D004347 | — | — | 5 | — | — | — | — | 5 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 1 | — | — | — | 3 | 4 |
Microbiota | D064307 | — | — | 1 | — | — | — | 2 | 3 |
Fasting | D005215 | EFO_0002756 | — | 2 | — | — | — | 1 | 3 |
Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | 1 | 2 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | — | — | — | — | 2 |
Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatitis | D010195 | HP_0001733 | K85 | — | — | — | — | 5 | 5 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 2 | 2 |
Disease-free survival | D018572 | EFO_0000409 | — | — | — | — | — | 2 | 2 |
Ischemic stroke | D000083242 | — | — | — | — | — | — | 2 | 2 |
Fertilization in vitro | D005307 | — | — | — | — | — | — | 2 | 2 |
Essential hypertension | D000075222 | — | I10 | — | — | — | — | 2 | 2 |
Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | — | — | — | 2 | 2 |
Precocious puberty | D011629 | — | E22.8 | — | — | — | — | 2 | 2 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
Drug common name | Metformin glycinate |
INN | metformin glycinate |
Description | Actoplus Met, Avandamet, Competact, Ebymect, Efficib, Eucreas, Fortamet, Glucovance, Glumetza, Icandra, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Metaglip, Prandimet, Qternmet, Qtrilmet, Ristfor, Segluromet, Synjardy, Trijardy, Velmetia, Vipdomet, Vokanamet, Xigduo, Zituvimet, Zomarist (metformin glycinate) is an unknown pharmaceutical. Metformin glycinate was first approved as Glucophage on 1995-03-03. It has been approved in Europe to treat type 2 diabetes mellitus. |
Classification | Unknown |
Drug class | hypoglycemics (phenformin type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 121369-64-0 |
RxCUI | — |
ChEMBL ID | CHEMBL2108299 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | YEI21W005Y (ChemIDplus, GSRS) |